Keros Therapeutics Inc. (KROS)

AI Score

Unlock

10.21

0.17 (1.69%)

At close: Apr 03, 2025, 2:09 PM

Dividends

No dividend history available for Keros Therapeutics Inc..

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Related Stocks

Company	Dividend Yield

Dividend Rankings

KROS News

1 week ago · Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet - zacks.com
4 weeks ago · Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - zacks.com
1 month ago · Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - zacks.com
1 month ago · INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS - accessnewswire.com
1 month ago · Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma - businesswire.com
2 months ago · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS - accessnewswire.com
2 months ago · Keros Therapeutics, Inc. Being Investigated on Behalf of Keros Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - accessnewswire.com
2 months ago · Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - accessnewswire.com
2 months ago · KROS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Keros Therapeutics, Inc. Shareholders Who Lost Money - accessnewswire.com
2 months ago · Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com